The cancer center will begin offering the treatment, which targets and destroys the prostate cancer specific biomarker PSMA+, in March, according to a Feb. 18 news release from Providence.
Previously, the treatment has been available only in the lower 48 states, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
